Keywords: enrollment, ends, ph, iii, nsclc, trial, tlr-9
Enrollment ends in Ph III NSCLC trial of TLR-9
Article | 16 April 2007
Massachusetts, USA-based Coley Pharmaceutical says that Pfizer, licensee for its Toll-like receptor 9 agonist drug candidate PF-3512676, has completed patient enrollment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
